Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer
The current LCMC study, the LCRF LEADER Neoadjuvant Screening Trial, is the fourth study conducted through the consortium and is a collaborative effort involving numerous academic study sites and pharmaceutical supporters.
Utilizing an umbrella trial design, the goal of the study is to screen for 10 actionable driver mutations in 1,000 lung cancer patients who are candidates for neoadjuvant therapy (additional therapy before surgery).
The LCMC4 screening study, together with matched industry-sponsored therapeutic trials, will provide critical data for informing treatment decisions in the neoadjuvant setting.
To Participate in LCMC Studies:
If you have been diagnosed with stage I, II, or III lung cancer for which surgery may be an option and are interested in participating in a LCMC study, discuss the study with your oncologist. Have more questions? Contact our Lung Cancer Support Line.
To View Participating Sites:
Click the state of interest on the map below or visit ClinicalTrials.gov.